From the Islet Cell and Regenerative Biology, Joslin Diabetes Center, Department of Medicine, Harvard Medical School, Harvard Stem Cell Institute, Boston, Massachusetts 02215.
the Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Illinois, Chicago, Illinois 60612.
J Biol Chem. 2019 Jan 18;294(3):1059-1069. doi: 10.1074/jbc.RA118.006031. Epub 2018 Nov 20.
FoxO proteins are major targets of insulin action, and FoxO1 mediates the effects of insulin on hepatic glucose metabolism. We reported previously that serpinB1 is a liver-secreted factor (hepatokine) that promotes adaptive β-cell proliferation in response to insulin resistance in the liver-specific insulin receptor knockout (LIRKO) mouse. Here we report that FoxO1 plays a critical role in promoting serpinB1 expression in hepatic insulin resistance in a non-cell-autonomous manner. Mice lacking both the insulin receptor and FoxO1 (LIRFKO) exhibit reduced β-cell mass compared with LIRKO mice because of attenuation of β-cell proliferation. Although hepatic expression of serpinB1 mRNA and protein levels was increased in LIRKO mice, both the mRNA and protein levels returned to control levels in LIRFKO mice. Furthermore, liver-specific expression of constitutively active FoxO1 in transgenic mice induced an increase in hepatic serpinB1 mRNA and protein levels in refed mice. Conversely, serpinB1 mRNA and protein levels were reduced in mice lacking FoxO proteins in the liver. ChIP studies demonstrated that FoxO1 binds to three distinct sites located ∼9 kb upstream of the gene in primary mouse hepatocytes and that this binding is enhanced in hepatocytes from LIRKO mice. However, adenoviral expression of WT or constitutively active FoxO1 and insulin treatment are sufficient to regulate other FoxO1 target genes (IGFBP-1 and PEPCK) but not serpinB1 expression in mouse primary hepatocytes. These results indicate that liver FoxO1 promotes serpinB1 expression in hepatic insulin resistance and that non-cell-autonomous factors contribute to FoxO1-dependent effects on serpinB1 expression in the liver.
FoxO 蛋白是胰岛素作用的主要靶标,FoxO1 介导胰岛素对肝葡萄糖代谢的影响。我们之前报道过,丝氨酸蛋白酶抑制剂 B1 是一种肝脏分泌的因子(肝分泌因子),可促进适应性β细胞增殖,以应对肝脏特异性胰岛素受体敲除(LIRKO)小鼠的胰岛素抵抗。在这里,我们报告 FoxO1 在非细胞自主方式中在肝胰岛素抵抗中促进 serpinB1 表达中起关键作用。由于β细胞增殖减弱,缺乏胰岛素受体和 FoxO1 的小鼠(LIRFKO)与 LIRKO 小鼠相比,β细胞质量减少。尽管 LIRKO 小鼠中 serpib1 mRNA 和蛋白水平增加,但 LIRFKO 小鼠中两种 mRNA 和蛋白水平均恢复至对照水平。此外,在转基因小鼠中肝特异性表达组成型激活的 FoxO1 可诱导再喂养小鼠肝 serpib1 mRNA 和蛋白水平增加。相反,在肝脏中缺乏 FoxO 蛋白的小鼠中,serpib1 mRNA 和蛋白水平降低。ChIP 研究表明,FoxO1 在原代小鼠肝细胞中结合到位于基因上游约 9kb 的三个不同位点,并且在 LIRKO 小鼠的肝细胞中这种结合增强。然而,WT 或组成型激活的 FoxO1 的腺病毒表达和胰岛素处理足以调节其他 FoxO1 靶基因(IGFBP-1 和 PEPCK),但不能调节小鼠原代肝细胞中 serpib1 的表达。这些结果表明,肝 FoxO1 促进肝胰岛素抵抗中的 serpib1 表达,并且非细胞自主因素有助于 FoxO1 对肝 serpib1 表达的依赖性影响。